Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions
Data confirm results from first Phase 3 trial, with 60% of Dupixent patients meeting the primary endpoint of itch reduction compared to 18% of placebo at 24 weeks
Additionally, nearly three times as many Dupixent patients experienced reduced skin lesions
Data continue to support well-established safety profile of Dupixent
Data to be submitted to regulatory authorities starting in H1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.